IBI397 or Combination Therapies in Patients With Advanced Malignancies
The primary objective of this phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI397 or its Combination Therapies in Patients with Advanced Malignancies
Advanced Malignancies
DRUG: IBI397|DRUG: IBI397+Sintilimab|DRUG: IBI397+Rituximab
Number of patients with treatment related AEs, Number of patients who experienced a treatment related AEs from the frist dose until 90 days after the last dose, Up to 90 days post last dose|Percentage of Subjects with Dose-Limiting Toxicities (DLTs), To evaluate the safety and tolerability of IBI397 alone or in combination with Sintilimab, Up to 28 Days following first dose
area under the plasma concentration-time curve (AUC), Up to 90 days post last dose|maximum concentration (Cmax), Up to 90 days post last dose|clearance (CL), Up to 90 days post last dose|volume of distribution (V), Up to 90 days post last dose|half-life (t1/2), Up to 90 days post last dose|anti-drug antibody (ADA), Number of Anti-Drug Antibodies (ADA) positive subjects will be counted and percentage of ADA positive subjects will be calculated to evaluate immunogenicity of IBI397, Up to 90 days post last dose|Objective response rate (ORR), Objective Response Rate (ORR) is the percentage of Complete Response (CR) plus partial response (PR) assessed per RECIST v1.1 criteria for solid tumors or per Lugano2014 criteria for lymphomas, Up to 2 years after enrollment
The primary objective of this phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI397 or its Combination Therapies in Patients with Advanced Malignancies